ArticlebioRxiv : the preprint server for biology2026
IL-6R blockade with tocilizumab disrupts pericyte- and tumor cell-driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer.
Róża Przanowska et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.